Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

JIANGSU, China, April 3, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone today with the first patient dosed in its First-in-human phase I clinical trial for RAG-01 conducted in collaboration with GenesisCare,Australia'...

2024-04-03 20:00 1023

Ascletis Announces Strategic Decisions on FXR agonist ASC42

HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42. After thorough analysis of the Phase II trial data of ASC42 for primary biliary cholangitis (PBC) (...

2024-04-03 17:10 1121

Nagase Viita Receives Highest "Platinum" Rating for Sustainability from EcoVadis

OKAYAMA, Japan, April 3, 2024 /PRNewswire/ -- Nagase Viita Co., Ltd., a NAGASE Group member headquartered in Okayama,Japan, has received the highest "Platinum" rating in a sustainability survey conducted by EcoVadis SAS ofFrance , one of the world's most trusted providers of business sustainabilit...

2024-04-03 14:00 1204

I-Mab Announces Closing of the Divestiture of Business Operations in China

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all condition...

2024-04-03 04:01 1227

GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

YONGIN, South Korea, April 2, 2024 /PRNewswire/ -- GC Cell , a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data f...

2024-04-02 23:00 1739

GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

VANCOUVER, BC, April 2, 2024 /PRNewswire/ -- WAT Medical Enterprise achieves a major milestone: HeadaTerm 2 receives the OTC clearance from the U.S. Food and Drug Administration (FDA), making it one of the only wearable anti-migraine devices that is available without a prescription in the U.S. U...

2024-04-02 21:00 1166

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

China Medical University Hospital Develops "AISIA" to Diagnose Acute Ischemic Stroke in 90 Seconds to Assist Doctors in Making Medical Decisions

TAICHUNG, Taiwan , April 2, 2024 /PRNewswire/ -- The Neurology Department of China Medical University Hospital (CMUH,Taiwan), teaming up with AI Center at CMUH, has established the AISIA (Artificial Intelligence for Stroke Image Analysis) platform, which contains the "NCCT-based Ischemic Stroke D...

2024-04-02 20:30 1256

China Medical University Hospital Develops

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

TAICHUNG, Taiwan, April 2, 2024 /PRNewswire/ -- The treadmill exercise test (TET) is an important tool for diagnosing coronary artery disease (CAD), but limited by time spent for the manual interpretation of a dozen charts and the challenges in identifying minor deviations. Traditionally, manual ...

2024-04-02 20:30 1450

China Medical University Hospital, Collaborated with Microsoft Taiwan, Launched GenAI: gHi System

gHi system is the world's first GenAI medical record system in Mandarin and reduce time spent by 75% TAICHUNG, Taiwan, April 2, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) and Microsoft Taiwan announced the Generative Healthcare Intelligent (gHi) System, which is being applied...

2024-04-02 20:30 1928

China Medical University Hospital, Collaborated with Microsoft Taiwan, Launched GenAI: gHi System

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company'sin vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the commencement ...

2024-04-02 20:00 1098

Gushengtang Releases 2023 Annual Results: Sustained Growth with Robust Profit Increase

GUANGZHOU, China, April 2, 2024 /PRNewswire/ -- On March 27th, Gushengtang announced its financial results for 2023. During the year, the company's revenue reached2.323 billion yuan, marking a 43% year-over-year increase; the adjusted net profit was305 million yuan, increased by 53.6% compared to...

2024-04-02 16:49 2853

23WELL, THE health supplement brand on the watch

LOS ANGELES, April 1, 2024 /PRNewswire/ -- Just earlier last month, the highly anticipated Natural Products Expo West 2024 concluded successfully inAnaheim, CA. As one of the world's largest leading health and nutrition exhibition, it hosted more than 65,000 registered attendees and 3,000+ exhibi...

2024-04-02 09:07 1597

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunotherapy success, pioneering next-gen personalized treatment approaches, supported by the AI-powered Lunit SCOPE suite SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading...

2024-04-01 21:00 1525

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO

～Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS inJapan and Asia～ TOKYO, April 1, 2024 /PRNewswire/ -- Aculys Pharma, Inc. ("Aculys"), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today ...

2024-04-01 14:30 1335

OFFICIAL LAUNCH OF THE NATIONAL UNIVERSITY SPINE INSTITUTE (NUSI): LEADING SPINE CARE INTO THE FUTURE

Public symposium by NUSI marks the end of a series of spine-related events that provide doctors with platform for professional development and networking SINGAPORE, March 30, 2024 /PRNewswire/ -- The National University Spine Institute (NUSI) is a new dedicated specialist spine institute under th...

2024-03-30 11:00 2416

Baird Medical Granted New Class III Certificate by China's NMPA for Ceramic Thyroid Ablation Needle

FRISCO, Texas, March 29, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced it has been granted a new Class III certificate by the National ...

2024-03-29 21:37 2231

LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)

* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC * FDA's Fast Track designation for LB-P8 underlines the urgent need for treatment options to fulfill the unmet medical needs of people affecte...

2024-03-29 21:00 2335

73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis

SAN FRANCISCO, March 29, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their cor...

2024-03-29 20:40 1841

Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SHANGHAI, March 29, 2024 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that th...

2024-03-29 20:00 1495

IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma

SHANGHAI and NANJING, China and SAN JOSE, Calif., March 29, 2024 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced thatChina National Medical Products Administratio...

2024-03-29 17:20 1337

1 2 3 456 7 8 ... 254